Skye Bioscience Files 8-K for Corporate Info Update
Ticker: SKYE · Form: 8-K · Filed: Feb 12, 2024 · CIK: 1516551
Complexity: simple
Sentiment: neutral
Topics: corporate-update, administrative, 8-K
TL;DR
**Skye Bioscience filed a routine 8-K to update its corporate contact info, no big news.**
AI Summary
Skye Bioscience, Inc. filed an 8-K on February 12, 2024, to update its corporate information, including its current name and business address at 11250 El Camino Real, Suite 100, San Diego, CA 92130. This filing primarily serves to keep the public record current, reflecting the company's identity and contact details. For investors, this matters as it confirms the company's official status and provides essential contact information, though it doesn't signal any operational changes or financial events.
Why It Matters
This filing ensures public records are current with Skye Bioscience's official name and address, which is important for regulatory compliance and investor communication.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no material impact on the company's operations or financial health.
Analyst Insight
This filing is purely administrative and does not contain information that would warrant immediate investment action. Investors should continue to monitor for more substantive operational or financial news.
Key Players & Entities
- Skye Bioscience, Inc. (company) — registrant
- Emerald Bioscience, Inc. (company) — former name of registrant
- Nemus Bioscience, Inc. (company) — former name of registrant
- LOAD GUARD LOGISTICS, INC. (company) — former name of registrant
- February 12, 2024 (date) — date of earliest event reported and filing date
- 11250 El Camino Real, Suite 100, San Diego, CA 92130 (address) — principal executive offices
- (858) 410-0266 (phone_number) — registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Skye Bioscience, Inc.?
The purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits,' primarily updating the company's corporate information, including its current name and business address, as of February 12, 2024.
What is the current business address of Skye Bioscience, Inc. as stated in the filing?
The current business address of Skye Bioscience, Inc. is 11250 El Camino Real, Suite 100, San Diego, CA 92130.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 12, 2024.
Has Skye Bioscience, Inc. operated under different names in the past?
Yes, Skye Bioscience, Inc. has operated under several former names, including Emerald Bioscience, Inc. (changed March 25, 2019), Nemus Bioscience, Inc. (changed October 30, 2014), and LOAD GUARD LOGISTICS, INC. (changed November 7, 2012).
What is the Commission File Number for Skye Bioscience, Inc.?
The Commission File Number for Skye Bioscience, Inc. is 000-55136.
Filing Stats: 623 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-02-12 16:18:20
Key Financial Figures
- $5 million — s resulting compliance with the minimum $5 million stockholders' equity requirement for in
Filing Documents
- skye-20240212.htm (8-K) — 29KB
- a991_unauditedproformabala.htm (EX-99.1) — 53KB
- 0001516551-24-000008.txt ( ) — 202KB
- skye-20240212.xsd (EX-101.SCH) — 2KB
- skye-20240212_lab.xml (EX-101.LAB) — 22KB
- skye-20240212_pre.xml (EX-101.PRE) — 11KB
- skye-20240212_htm.xml (XML) — 2KB
01 Other Events
Item 8.01 Other Events. The following unaudited pro forma balance sheet has been prepared to illustrate the impact of a number of events that followed the close of the Company's third quarter ended September 30, 2023, including (i) the Company's receipt of proceeds from the private placement of the Company's common stock on January 31, 2024, (ii) the sale of real-estate on January 19, 2024 and (iii) the increase to the company's authorized shares of capital stock, and the Company's resulting compliance with the minimum $5 million stockholders' equity requirement for initial listing on The Nasdaq Capital Market. In that regard, the Company believes that as of the date of this Form 8-K filing, stockholders' equity exceeds $5 million. The unaudited pro forma balance sheet is based on the Company's unaudited balance sheet as of September 30, 2023, as contained in the Company's 10-Q for the quarter then ended, filed with the Securities and Exchange Commission on November 14, 2023, adjusted to reflect the subsequent events after the balance sheet date of September 30, 2023, through the date of filing, as set out in Note 13 of the 10-Q and as described above, as if the events occurred on September 30, 2023. This unaudited pro forma balance sheet is for informational purposes only, and should be read in conjunction with the more detailed unaudited condensed consolidated financial statements and related notes thereto included in the Company's Form 10-Q for the quarter ended September 30, 2023.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Unaudited Pro Forma Balance Sheet of the Company as of September 30, 2023 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: February 12, 2024 /s/ Kaitlyn Arsenault Name: Kaitlyn Arsenault Title: Chief Financial Officer